The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers

被引：0
|
作者：
Gane, Edward J. [1 ]
Schwabe, Christian [2 ]
Liu, Jieming [3 ]
Stamm, Luisa M. [3 ]
Kitrinos, Kathryn M. [3 ]
Knox, Steven J. [3 ]
Anderson, Michele [3 ]
Wang, Grace [3 ]
Zomorodi, Katie [3 ]
机构：
[1] Univ Auckland, Auckland, New Zealand
[2] New Zealand Clin Res, Auckland, New Zealand
[3] Assembly Biosci, San Francisco, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-186
引用
收藏
页码：S1161 / S1162
页数：2
相关论文
共 50 条
  • [41] A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled GDC-0214, a JAK1 Inhibitor, as Single- and Multiple-Ascending Doses in Healthy Volunteers
    Owen, Ryan
    Galanter, Joshua
    Zhu, Rui
    Cai, Fang
    Tom, Jennifer
    Wynne, Chris
    Durk, Matthew
    Chen, Liuxi
    Kenny, Jane
    She, Gao-hong
    Vadhavkar, Shweta
    Hwang, Olivia
    Chen, Hubert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB17 - AB17
  • [42] Results of a phase 1 placebo-controlled trial in healthy volunteers to examine the safety tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing
    Verloes, Rene
    Abou Farha, Khalid
    van Vliet, Andre
    van't Klooster, Gerben
    Aharchi, Fatima
    Marien, Kris
    de Kock, Herman
    Simmen, Kenneth
    HEPATOLOGY, 2007, 46 (04) : 823A - 824A
  • [43] Results from a phase 1 study investigating the safety and pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in subjects with varying degrees of hepatic function
    Hui, James
    Halvorsen, Yuan-Di
    Bond, Mary
    Murphy, Brian
    Isaacsohn, Jonathan
    Freeman, Mason W.
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 246 - 247
  • [44] Safety, Tolerability, Pharmacokinetics (pk) And Pharmacodynamics (pd) Of Gsk2339345-Novel Sodium Channel Blocker. Results From Two Phase I Studies In Healthy Volunteers
    Marks-Konczalik, J.
    Murdoch, R. D.
    Kelly, K. L.
    Cheesbrough, A.
    Siederer, S. K.
    Singh, D.
    Smith, J. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [45] Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers
    Erpenbeck, Veit J.
    Vets, Eva
    Gheyle, Lien
    Osuntokun, Wande
    Larbig, Michael
    Neelakantham, Srikanth
    Sandham, David
    Dubois, Gerald
    Elbast, Walid
    Goldsmith, Paul
    Weiss, Markus
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (04): : 306 - 313
  • [46] A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys
    Lauritzen, Brian
    Bjelke, Mads
    Rossen, Marie
    Skydsgaard, Mikala
    Kjalke, Marianne
    Bjorkdahl, Olle
    Kjellev, Stine L.
    BLOOD, 2020, 136
  • [47] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
  • [48] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    Wang, Michael
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan Ni
    Lewis, Katharine L.
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian W.
    Lewis, David John
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Jonathon B.
    Barve, Minal
    Ghia, Paolo
    Eyre, Toby A.
    Yin, Ming
    Nair, Binoj
    Tsai, Donald
    Ku, Nora C.
    Mato, Anthony
    Cheah, Chan Yoon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
  • [49] Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants
    Zhang, Xiaoran
    Shi, Gexin
    Li, Shaorong
    Rao, Jing
    Wen, Qing
    Zhao, Hengli
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (06): : 639 - 644
  • [50] Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study
    Olson, Allan
    Hartung, Jeffrey
    Timony, Gregg
    Peach, Robert
    Boehm, Marcus
    Rosen, Hugh
    Smith, Heather
    Pan, Christine
    Brooks, Jennifer
    Gujrathi, Sheila
    NEUROLOGY, 2013, 80
12345